SCHEMBL30997656

SCHEMBL30997656

Cc1cc(Nc2ncc(C#N)c(Nc3cccc(N4CCOC4=O)n3)n2)ccc1C1CCN(C)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WEE1 P30291 4/20 0.48
▸ SLC2A1 P11166 1/20 0.44
▸ JAK2 O60674 4/20 0.43
▸ CSF1R P07333 2/20 0.42
▸ CDK4 P11802 2/20 0.42
▸ CDK6 Q00534 2/20 0.42
▸ PIK3CD O00329 1/20 0.42
▸ TBK1 Q9UHD2 6/20 0.41
▸ ALK Q9UM73 1/20 0.41
▸ TNK2 Q07912 1/20 0.41
▸ BRD4 O60885 1/20 0.40
▸ PKMYT1 Q99640 1/20 0.39
▸ CCNK O75909 1/20 0.39
▸ CCNA2 P20248 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CDK7 P50613 1/20 0.39
▸ CDK9 P50750 1/20 0.39
▸ CCNH P51946 1/20 0.39
▸ CDK5 Q00535 1/20 0.39
▸ CDK5R1 Q15078 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29310126 1.00 WEE1 (0.48) WEE1SLC2A1JAK2CSF1RCDK4
SCHEMBL29310208 0.87 WEE1 (0.49) WEE1SLC2A1JAK2CSF1RCDK4
SCHEMBL30997635 0.87 WEE1 (0.49) WEE1SLC2A1JAK2CSF1RCDK4
SCHEMBL30997668 0.84 WEE1 (0.48) WEE1SLC2A1TNK2PKMYT1SYK
SCHEMBL29310127 0.84 WEE1 (0.48) WEE1SLC2A1TNK2PKMYT1SYK
SCHEMBL30997675 0.79 SLC2A1 (0.43) WEE1SLC2A1JAK2CSF1RCDK4
SCHEMBL29310124 0.79 SLC2A1 (0.43) WEE1SLC2A1JAK2CSF1RCDK4
SCHEMBL30997604 0.79 WEE1 (0.44) WEE1SLC2A1TNK2PKMYT1SYK
SCHEMBL30997613 0.79 SLC2A1 (0.43) WEE1SLC2A1JAK2CSF1RCDK4
SCHEMBL29310125 0.79 SLC2A1 (0.43) WEE1SLC2A1JAK2CSF1RCDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B WEE1 1/4885SLC2A1 4591/4885JAK2 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback